Shuh Narumiya Selected Research

Edema (Dropsy)

1/2024	Sphingosine-1-phosphate receptor 1/5 selective agonist alleviates ocular vascular pathologies.
10/2023	Thromboxane prostanoid signaling in macrophages attenuates lymphedema and facilitates lymphangiogenesis in mice : TP signaling and lymphangiogenesis.
2/2014	Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation.
1/2014	Role of the prostaglandin E2 EP1 receptor in traumatic brain injury.
3/2013	Anti-inflammatory role of PGD2 in acute lung inflammation and therapeutic application of its signal enhancement.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuh Narumiya Research Topics

Disease

60	Inflammation (Inflammations) 10/2023 - 04/2002
24	Neoplasms (Cancer) 12/2022 - 01/2002
10	Pain (Aches) 05/2011 - 07/2003
9	Asthma (Bronchial Asthma) 01/2023 - 04/2002
9	Contact Dermatitis (Eczema, Contact) 10/2019 - 06/2003
8	Fever (Fevers) 01/2017 - 09/2003
8	Stroke (Strokes) 10/2012 - 03/2007
7	Intracranial Aneurysm (Cerebral Aneurysm) 01/2019 - 01/2014
7	Carcinogenesis 07/2015 - 01/2002
6	Hypersensitivity (Allergy) 01/2023 - 08/2003
6	Wounds and Injuries (Trauma) 04/2022 - 10/2006
6	Ischemia 01/2020 - 11/2003
6	Infarction (Infarctions) 10/2012 - 03/2007
6	Brain Ischemia (Cerebral Ischemia) 10/2012 - 03/2007
5	Edema (Dropsy) 01/2024 - 03/2013
5	Hypertension (High Blood Pressure) 01/2023 - 01/2005
5	Alzheimer Disease (Alzheimer's Disease) 03/2015 - 11/2007
5	Fibrosis (Cirrhosis) 07/2012 - 09/2003
5	Hyperalgesia 05/2011 - 07/2003
4	Infections 01/2022 - 08/2008
4	Rheumatoid Arthritis 09/2020 - 02/2006
4	Atopic Dermatitis (Atopic Eczema) 11/2019 - 08/2003
4	Autoimmune Diseases (Autoimmune Disease) 10/2019 - 03/2016
4	Neoplasm Metastasis (Metastasis) 12/2015 - 10/2006
4	Brain Injuries (Brain Injury) 01/2014 - 01/2009
4	Ischemic Stroke 01/2014 - 03/2009
4	Colonic Neoplasms (Colon Cancer) 10/2006 - 01/2002
4	Hypertrophy 07/2005 - 06/2002
3	Colitis 08/2020 - 04/2002
3	Immune System Diseases (Immune Disorders) 10/2019 - 01/2010
3	Necrosis 10/2019 - 11/2009
3	Reperfusion Injury 01/2018 - 05/2004
3	Dermatitis 01/2018 - 10/2013
3	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 01/2003
3	Pathologic Processes 03/2016 - 08/2008
3	Melanoma (Melanoma, Malignant) 12/2015 - 01/2008
3	Gliosis 01/2014 - 04/2006
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2014 - 12/2009
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2012 - 03/2007
3	Vascular Remodeling 10/2011 - 03/2010
3	Cardiomegaly (Heart Hypertrophy) 02/2011 - 11/2003
3	Atherosclerosis 02/2011 - 09/2004
3	Tachycardia (Tachyarrhythmias) 02/2011 - 11/2003
3	Disease Progression 07/2010 - 12/2009
2	Pneumonia (Pneumonitis) 01/2023 - 03/2013

Drug/Important Bio-Agent (IBA)

80	ProstaglandinsIBA 10/2023 - 01/2002
32	Dinoprostone (PGE2)FDA Link 10/2023 - 11/2003
19	Prostaglandins EIBA 07/2012 - 01/2002
18	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2023 - 01/2002
14	Prostaglandin D2IBA 01/2022 - 04/2002
11	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2018 - 10/2002
11	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 07/2012 - 01/2002
10	CytokinesIBA 10/2023 - 09/2003
10	Messenger RNA (mRNA)IBA 01/2022 - 01/2002
10	Proteins (Proteins, Gene)FDA Link 01/2014 - 01/2002
8	ThromboxanesIBA 10/2023 - 01/2004
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2002
8	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017 - 07/2002
8	Prostaglandin Receptors (Prostaglandin Receptor)IBA 05/2011 - 04/2002
7	AntigensIBA 10/2019 - 06/2003
7	ChemokinesIBA 01/2019 - 03/2010
7	Epoprostenol ReceptorsIBA 01/2018 - 09/2004
7	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2017 - 01/2002
7	EnzymesIBA 07/2015 - 09/2004
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2014 - 01/2004
6	Prostaglandins DIBA 03/2013 - 06/2002
5	Arachidonic Acid (Vitamin F)IBA 10/2023 - 08/2003
4	SaltsIBA 01/2023 - 01/2005
4	LigandsIBA 12/2022 - 02/2007
4	LipidsIBA 12/2022 - 02/2003
4	prostaglandin D2 receptorIBA 01/2022 - 08/2014
4	Transforming Growth Factor beta (TGF-beta)IBA 01/2022 - 07/2002
4	Dextrans (Dextran)FDA Link 08/2020 - 04/2002
4	Indomethacin (Indometacin)FDA LinkGeneric 11/2019 - 07/2003
4	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2017 - 09/2005
4	Thromboxane Receptors (Thromboxane Receptor)IBA 07/2015 - 09/2004
4	salicylhydroxamic acid (SHAM)IBA 01/2014 - 04/2007
4	prostaglandin F2alpha receptorIBA 10/2013 - 01/2009
3	Thromboxane A2 (A2, Thromboxane)IBA 10/2023 - 05/2005
3	RNA (Ribonucleic Acid)IBA 04/2022 - 01/2019
3	EicosanoidsIBA 01/2022 - 01/2008
3	Phospholipases (Phospholipase)IBA 01/2022 - 12/2009
3	Interleukin-23 (Interleukin 23)IBA 01/2019 - 08/2010
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2018 - 06/2014
3	HaptensIBA 01/2018 - 10/2009
3	AzoxymethaneIBA 01/2017 - 01/2002
3	Prostaglandin-E SynthasesIBA 01/2017 - 12/2015
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2017 - 04/2013
3	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2017 - 04/2002
3	Interleukin-6 (Interleukin 6)IBA 07/2015 - 02/2006
3	Prostaglandins FIBA 10/2012 - 05/2005
3	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 03/2012 - 11/2007
3	4- (4- cyano- 2- (2- (4- fluoronaphthalen- 1- yl)propionylamino)phenyl)butyric acidIBA 02/2010 - 04/2002
2	ASP4058IBA 01/2024 - 01/2017
2	Angiotensin IIIBA 01/2023 - 08/2010

Therapy/Procedure

7	Therapeutics 01/2022 - 12/2009
4	Chemoprevention 01/2017 - 02/2005
3	Ligation 08/2019 - 01/2014
2	Drug Therapy (Chemotherapy) 02/2024 - 10/2019
2	Lasers (Laser) 01/2024 - 01/2019